Oculis Holding AG
No SEC Form 4 filings for $OCS in the last 30 days.
See all $OCS insider activity →Oculis Holding AG (OCS) agreed to acquire worldwide rights to Accure Therapeutics’ Privosegtor (ACT-01) and ACT-02. Consideration is $3.8m (or CHF 3.1m) upfront plus up to 2.05m OCS shares, including lockup and milestone earnouts. OCS shares rose in premarket. Deal closes by Feb 28, 2027 (ACT-01) and Mar 31, 2027 (ACT-02).
Mitie confirmed it agreed to a 221p-per-share offer from OCS, owned by US private equity Clayton Dubilier & Rice, in a £3.1bn deal to merge immigration removal centre operations and other facilities services. Mitie reported £319m revenue for its immigration and justice division in its latest year. The merger is expected to complete in Q1 2027; Mitie shares rose over 38%.
European markets rose on Tuesday. Stoxx Europe 600 gained 0.56% to 643.19, with FTSE 100 up 0.58%, DAX up 0.66%, CAC 40 up 0.28%, FTSE MIB up 0.81%, and IBEX 35 up 0.9%. UK unemployment held at 4.9% (ONS). Company moves included Shell, BP, TotalEnergies, ASM International, Infineon, Novartis, Julius Baer, Mitie, and Boliden.
Over the past 7 days, alphai's AI scored 1 news story mentioning OCS (Oculis Holding AG). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OCS coverage spans financial news, mergers & acquisitions and market movers.
Deal terms and milestone-linked earnout shares create a near-term re-rating catalyst for OCS, with execution risk into 2027 closings.
OCS faces a takeover bid dynamic where acceptance, financing, and deal conditions drive the stock’s risk/reward.
Deal news can drive immediate repricing for the acquirer and related financing expectations, though the article focuses on Mitie’s move.
Randomization start is a concrete clinical-trial execution milestone for licaminlimab’s FDA-aligned registrational program, supporting progression risk reduction.
Conference participation plus reiterated late-stage pipeline milestones can support sentiment, but it is not a new clinical/regulatory datapoint.
alphai scores every news story that mentions OCS with an AI model for sentiment and relevance, and aggregates insider trades from Oculis Holding AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Oculis Holding AG (OCS) agreed to acquire worldwide rights to Accure Therapeutics’ Privosegtor (ACT-01) and ACT-02. Consideration is $3.8m (or CHF 3.1m) upfront plus up to 2.05m OCS shares, including lockup and milestone earnouts. OCS shares rose in premarket. Deal closes by Feb 28, 2027 (ACT-01) and Mar 31, 2027 (ACT-02).
5 min readMitie confirmed it agreed to a 221p-per-share offer from OCS, owned by US private equity Clayton Dubilier & Rice, in a £3.1bn deal to merge immigration removal centre operations and other facilities services. Mitie reported £319m revenue for its immigration and justice division in its latest year. The merger is expected to complete in Q1 2027; Mitie shares rose over 38%.
6 min readEuropean markets rose on Tuesday. Stoxx Europe 600 gained 0.56% to 643.19, with FTSE 100 up 0.58%, DAX up 0.66%, CAC 40 up 0.28%, FTSE MIB up 0.81%, and IBEX 35 up 0.9%. UK unemployment held at 4.9% (ONS). Company moves included Shell, BP, TotalEnergies, ASM International, Infineon, Novartis, Julius Baer, Mitie, and Boliden.
5 min readOculis Holding AG said the first patient was randomized in its FDA-aligned, genotype-based PREDICT-1 registrational trial of licaminlimab for dry eye disease. The randomized, double-masked, vehicle-controlled study plans ~160 patients, targeting a specific TNFR1 genotype; primary endpoint is change in global ocular discomfort severity score at Day 29. About 70% of sites are activated and patients are in run-in.
4 min readOculis Holding AG (Nasdaq: OCS; XICE: OCS) said management will join a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9 in Miami. The company plans to update its late-stage pipeline, including Privosegtor (FDA Breakthrough Therapy and EMA PRIME for optic neuritis) and Licaminlimab (PREDICT-1 trial for genotype-based dry eye disease).
3 min readNeedham & Company LLC cut its Oculis (NASDAQ: OCS) price target to $38 from $46 in a Monday note, while keeping a “buy” rating, implying 67.39% upside from the prior close, according to Benzinga. Other firms cited mixed views, with targets ranging from $42 to $75. OCS last reported May 8 EPS of -$0.63 vs -$0.49 consensus.
4 min readOculis reported topline Phase 3 DIAMOND-1 and DIAMOND-2 results for OCS-01 eye drops in diabetic macular edema. The primary BCVA (ETDRS) endpoint at week 52 was not met in either trial, and the ≥15-letter BCVA gain secondary endpoint also was not met. Retinal thickness decreased persistently vs vehicle. Oculis said it will not pursue an FDA filing for DME. Cash: $278M (as of Mar. 31, 2026).
4 min readOculis (NASDAQ: OCS) saw multiple analyst updates. On May 20, Guggenheim began coverage with a Buy rating and $75 price target and upgraded to Strong-Buy. On May 18, JPMorgan raised its target to $42 and kept an Overweight rating. On May 12, Needham raised to $46 (Buy) and HC Wainwright to $47 (Buy). Weiss reaffirmed a Sell (d-) on April 21.
1 min readOculis (NASDAQ: OCS) saw multiple analyst changes. On May 20, Guggenheim initiated coverage with a buy rating and $75 price target and upgraded to strong-buy. JPMorgan raised its target to $42 (from $38) with an overweight rating on May 18. Needham lifted to $46 and HC Wainwright to $47, both with buy ratings on May 12. Weiss reaffirmed a sell (d-) on April 21.
2 min readOculis Holding AG announced the publication of notifications regarding transactions by persons discharging managerial responsibilities. These notifications specifically detail the purchase of ordinary shares by a member of the company's Board of Directors. The press release also includes links to the specific notification documents from March 12 and March 13, 2026.
2 min read
